Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/22/2026

Eligibility Criteria for Repatha (Evolocumab)

Patients with Clinical ASCVD

  • The American College of Cardiology recommends Repatha for patients with a history of multiple major ASCVD events, such as recent acute coronary syndrome, history of myocardial infarction, history of ischemic stroke, or symptomatic peripheral arterial disease, despite maximally tolerated statin therapy plus ezetimibe 1, 2
  • Patients with one major ASCVD event plus multiple high-risk conditions, including age ≥65 years, heterozygous familial hypercholesterolemia, history of coronary revascularization, diabetes, hypertension, CKD, current smoking, or persistently elevated LDL-C ≥100 mg/dL, may be eligible for Repatha 1, 2
  • The American College of Cardiology recommends Repatha for patients with LDL-C ≥70 mg/dL despite maximally tolerated statin therapy plus ezetimibe 3, 2

Patients with Familial Hypercholesterolemia

  • The European Heart Journal recommends Repatha for patients with heterozygous familial hypercholesterolemia (HeFH) aged 30-75 years with LDL-C ≥100 mg/dL despite maximally tolerated statin plus ezetimibe 4, 5
  • Patients with HeFH and additional risk factors, such as diabetes with target organ damage, lipoprotein(a) >50 mg/dL, or major risk factors, may be eligible for Repatha with LDL-C ≥140 mg/dL 6
  • The European Heart Journal recommends Repatha for patients with homozygous familial hypercholesterolemia (HoFH) who have some residual LDL receptor activity (>2%) 6, 7

Special Considerations

  • The American Diabetes Association recommends Repatha for patients with diabetes and ASCVD, as they show greater absolute risk reduction with PCSK9 inhibitor therapy compared to those without diabetes 8, 9
  • Repatha is particularly beneficial for diabetes patients with target organ damage or additional major risk factors 6, 8

Monitoring and Response Assessment

  • The European Heart Journal recommends assessing LDL-C levels 4 weeks after initiating Repatha therapy 6, 7
  • Before considering Repatha, the European Heart Journal recommends ensuring patient adherence to statin and ezetimibe therapy 6
  • The American College of Cardiology recommends considering cost-effectiveness in the decision-making process for Repatha therapy 9
  • Ezetimibe should be tried before Repatha due to its lower cost and established safety profile, as recommended by the American College of Cardiology and the American Diabetes Association 3, 9

Lipid-Lowering Therapy with PCSK9 Inhibitors

Indications for PCSK9 Inhibitors

  • The American College of Cardiology recommends adding a PCSK9 inhibitor when LDL-C remains ≥70 mg/dL (≥1.8 mmol/L) despite maximally tolerated statin plus ezetimibe therapy in patients with clinical ASCVD who are at very high risk 10, 11
  • The American College of Cardiology suggests that PCSK9 inhibitors can be added to ezetimibe in patients with documented statin intolerance who have clinical ASCVD and LDL-C ≥70 mg/dL 12, 13
  • For patients with severe primary hypercholesterolemia, the American College of Cardiology recommends adding a PCSK9 inhibitor when LDL-C remains ≥100 mg/dL (≥2.6 mmol/L) on maximally tolerated statin plus ezetimibe 10, 11

Special Populations

  • The American College of Cardiology recommends adding a PCSK9 inhibitor when LDL-C remains ≥100 mg/dL (≥2.6 mmol/L) despite maximally tolerated statin plus ezetimibe in patients with heterozygous familial hypercholesterolemia aged 30-75 years 10, 14
  • The European Society of Cardiology recommends a more aggressive LDL-C target of <55 mg/dL (<1.4 mmol/L) for very high-risk patients, and suggests adding a PCSK9 inhibitor when this target is not achieved on maximal statin plus ezetimibe 14, 15

Clinical Efficacy and Monitoring

  • PCSK9 inhibitors provide 50-65% additional LDL-C reduction when added to statin therapy, with mean LDL-C levels of approximately 35 mg/dL achievable 12, 13
  • Both evolocumab and alirocumab have demonstrated a 15% relative risk reduction in major adverse cardiovascular events, with an absolute risk reduction of 1.5-1.6% over 2-3 years 11

PCSK9 Inhibitor Therapy in Hypercholesterolemia and Cardiovascular Disease

Primary Indication: Secondary Prevention in ASCVD

  • The American Diabetes Association recommends adding a PCSK9 inhibitor to maximally tolerated statin plus ezetimibe therapy when LDL cholesterol remains ≥70 mg/dL in patients with established atherosclerotic cardiovascular disease, targeting an LDL-C goal of <55 mg/dL 16
  • For patients with established cardiovascular disease, PCSK9 inhibitors provide a 15-20% relative risk reduction in major adverse cardiovascular events when added to statin therapy 16

Treatment Algorithm

  • The American College of Cardiology recommends high-intensity statin therapy as the foundation for patients aged 40-75 years with diabetes and ASCVD, targeting ≥50% LDL-C reduction from baseline 16
  • The European Society of Cardiology suggests adding ezetimibe before considering PCSK9 inhibitors due to lower cost and established safety profile 16
  • For secondary prevention, target LDL-C <55 mg/dL and add PCSK9 inhibitor if LDL-C remains ≥70 mg/dL despite maximally tolerated statin plus ezetimibe 16

Special Populations

  • The European Atherosclerosis Society recommends adding PCSK9 inhibitor to ezetimibe in patients with documented statin intolerance who have clinical ASCVD and LDL-C ≥70 mg/dL, with alirocumab showing fewer skeletal muscle-related adverse events compared to ezetimibe or atorvastatin rechallenge 17
  • Diabetes patients with ASCVD derive particular benefit from PCSK9 inhibitor therapy, with greater absolute risk reduction compared to non-diabetic patients 16
  • No increase in glycated hemoglobin or fasting plasma glucose during PCSK9 inhibitor treatment, and no excess risk for diabetes development with very low LDL-C levels (<25 mg/dL) 18

Monitoring and Safety

  • Assess LDL-C response 4 weeks after initiating therapy 18
  • Safety profile over 2-3 years of follow-up shows no increase in adverse events, including severe muscle symptoms, liver enzyme elevation, cognitive adverse events, or increased risk of hemorrhagic stroke with very low LDL-C levels 18

Cost-Effectiveness Considerations

  • Prioritize PCSK9 inhibitors for very high-risk patients with substantially elevated LDL-C levels despite maximally tolerated statin plus ezetimibe therapy to optimize cost-effectiveness 19
  • Patients with multiple major ASCVD events represent the most cost-effective target population 19

PCSK9 Inhibitors for High Cholesterol Management

Introduction to PCSK9 Inhibitor Therapy

  • The European Heart Journal recommends assessing LDL-C response after 4 weeks of initiating high-intensity statin therapy, with PCSK9 inhibitors considered for addition in specific patient populations 20
  • For patients with heterozygous familial hypercholesterolemia (FH) without clinical atherosclerotic cardiovascular disease (ASCVD), the European Heart Journal suggests adding PCSK9 inhibitors when LDL-C remains >180 mg/dL or >140 mg/dL with additional risk factors 20
  • The European Heart Journal indicates that PCSK9 inhibitors can be used as adjunct therapy in homozygous FH for patients with residual LDL receptor activity >2% 20
  • Very low LDL-C levels (<25 mg/dL) achieved with PCSK9 inhibitors show no safety concerns, including no increase in adverse events, liver enzyme elevation, cognitive adverse events, or increased risk of hemorrhagic stroke, according to the European Heart Journal 20
  • The European Heart Journal recommends assessing LDL-C response 4 weeks after initiating PCSK9 inhibitor therapy, with continued monitoring for cardiovascular events and safety parameters 20

Repatha (Evolocumab) and Statin Therapy Indication

Primary Indication: Secondary Prevention in ASCVD

  • The American Diabetes Association recommends Repatha for patients with established atherosclerotic cardiovascular disease (ASCVD) who have LDL-C ≥70 mg/dL despite maximally tolerated high-intensity statin therapy plus ezetimibe, targeting an LDL-C goal of <55 mg/dL 21
  • The European Society of Cardiology suggests that the foundation of therapy must be maximally tolerated high-intensity statin therapy before considering Repatha, with a stepwise approach critical for statins remaining first-line therapy for all patients at high cardiovascular risk 22

Critical Stepwise Algorithm

  • The American Diabetes Association recommends initiating high-intensity statin therapy targeting ≥50% LDL-C reduction from baseline, with Repatha added only if LDL-C remains ≥70 mg/dL despite maximally tolerated statin plus ezetimibe 21
  • The European Society of Cardiology suggests adding ezetimibe if LDL-C remains ≥70 mg/dL after maximally tolerated statin therapy, with ezetimibe always tried before Repatha due to lower cost and established safety profile 21

Special Considerations

  • The European Society of Cardiology recommends that for patients who cannot tolerate any statin regimen despite trying at least three different statins, Repatha can be added to ezetimibe alone if they have clinical ASCVD and LDL-C ≥70 mg/dL 22

Alirocumab Therapy for Very High‑Risk Atherosclerotic Cardiovascular Disease

Guideline Recommendations (ACC/AHA)

  • Statin‑first strategy: High‑intensity statin therapy should be maximized to achieve ≥50 % LDL‑C reduction from baseline before any additional agents are considered. This is the foundational recommendation of the ACC/AHA guidelines. 23
  • Add ezetimibe before PCSK9 inhibition: If LDL‑C remains ≥70 mg/dL on maximally tolerated statin, ezetimibe 10 mg daily is recommended (Class I). 23
  • Add alirocumab for very high‑risk patients: When LDL‑C is still ≥70 mg/dL despite statin + ezetimibe, alirocumab is advised for very high‑risk patients (Class IIa). 23

Patient Selection – Definition of “Very High‑Risk”

  • Major ASCVD events (e.g., recent acute coronary syndrome within 12 months, prior myocardial infarction, ischemic stroke, or symptomatic peripheral arterial disease) qualify a patient as very high‑risk. 23
  • High‑risk conditions that, when combined with a single major event, also meet the very high‑risk definition include chronic kidney disease with eGFR 15–59 mL/min/1.73 m². 24

Clinical Evidence – ODYSSEY OUTCOMES Trial

  • Trial population: 18,924 patients with a recent acute coronary syndrome (1–12 months prior) and LDL‑C ≥ 70 mg/dL despite maximally tolerated statin ± ezetimibe; 28.8 % had diabetes. Randomization to alirocumab or placebo, median follow‑up 2.8 years. 25
  • Dosing regimen: Start alirocumab 75 mg subcutaneously every 2 weeks; titrate to 150 mg every 2 weeks at week 12 if LDL‑C remains ≥70 mg/dL at week 8. Target LDL‑C during the trial was 25–50 mg/dL. 25
  • Efficacy – primary composite endpoint: Occurred in 9.5 % of alirocumab‑treated patients vs 11.1 % of placebo (hazard ratio 0.85; 95 % CI 0.78–0.93; p < 0.001). This represents a 15 % relative risk reduction (1.6 % absolute risk reduction). 24
  • Diabetes subgroup: Absolute risk reduction was 2.3 % (95 % CI 0.4–4.2) in patients with diabetes, compared with 1.2 % in pre‑diabetes and normoglycemic groups. The greater benefit supports preferential use in diabetic ASCVD patients. 26

Safety Profile

  • Overall safety: Over 2.8 years, alirocumab showed no increase in adverse events versus placebo. 25
  • Very low LDL‑C (<25 mg/dL): No excess in cognitive impairment, liver enzyme elevation, hemorrhagic stroke, or new‑onset diabetes was observed. 25
  • Statin‑intolerant patients (ODYSSEY ALTERNATIVE): Skeletal‑muscle‑related adverse events occurred in 32.5 % with alirocumab versus 41.1 % with ezetimibe and 46 % with atorvastatin rechallenge. 27

Monitoring and Dose Adjustment

  • LDL‑C assessment: Measure LDL‑C 4 weeks after initiating alirocumab. 25
  • Dose titration: Adjust dose at week 12 based on LDL‑C measured at week 8; increase to 150 mg if LDL‑C ≥70 mg/dL. 25
  • LDL‑C targets: Aim for <55 mg/dL in very high‑risk ASCVD patients; consider <40 mg/dL for those with recurrent events. 25
  • De‑intensification caveat: If two consecutive LDL‑C values fall below 25 mg/dL, clinicians should use judgment to consider dose reduction, as long‑term safety of such low levels remains uncertain. 23

Alternative PCSK9‑Inhibitor Options

Agent Trial Relative Risk Reduction Absolute Risk Reduction Follow‑up Dosing Options
Evolocumab (FOURIER) ASCVD patients with LDL‑C ≥ 70 mg/dL on max statin ± ezetimibe 15 % 1.5 % 2.2 years 140 mg q2 weeks or 420 mg monthly
Inclisiran (ORION‑10/11) Ongoing outcome trials — (LDL‑C reduction 50–52 %) — — Day 1, Day 90, then every 6 months

*Evolocumab’s efficacy mirrors that of alirocumab, while inclisiran offers less frequent dosing but lacks mature cardiovascular outcome data. 23

Cost‑Effectiveness Considerations

  • PCSK9 inhibitors are high‑cost monoclonal antibodies requiring repeated injections, which contributed to a Class IIa (rather than Class I) recommendation despite robust efficacy. 23
  • Prioritizing patients with multiple major ASCVD events maximizes absolute benefit and cost‑effectiveness. 28
  • Initiating therapy with ezetimibe first is encouraged because of its lower cost and proven safety. 23

Common Clinical Pitfalls (ACC/AHA)

  • Skipping maximized statin therapy before PCSK9 initiation reduces cost‑effectiveness and contravenes guideline sequencing. 23
  • Omitting ezetimibe leads to unnecessary PCSK9 use; most patients achieve LDL‑C targets with ezetimibe added to statin. 23
  • Prescribing PCSK9 inhibitors to patients who do not meet very high‑risk criteria disregards the Class IIa indication. 23
  • Failing to verify adherence to statin and ezetimibe before escalation may result in suboptimal therapy.

All facts are derived from ACC/AHA guideline statements and the cited clinical trials.

LDL‑C Management in Very High‑Risk Atherosclerotic Cardiovascular Disease (ASCVD) Patients

Foundations of Lipid Therapy

  • The American College of Cardiology (ACC) recommends initiating high‑intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) for all patients with established ASCVD, aiming for ≥50 % LDL‑C reduction from baseline. 29
  • If LDL‑C remains ≥70 mg/dL on maximally tolerated statin, the ACC advises adding ezetimibe 10 mg daily before considering PCSK9 inhibition, because of its lower cost and established safety profile. [29][30]

Criteria for Adding Alirocumab (PCSK9 Inhibitor)

  • According to the ACC, alirocumab should be added when LDL‑C stays ≥70 mg/dL despite statin + ezetimibe in very high‑risk patients (e.g., recent acute coronary syndrome within 1–12 months, median 2.6 months in ODYSSEY OUTCOMES). The target is LDL‑C <55 mg/dL and at least a 50 % reduction from baseline. 29

Clinical Efficacy of Alirocumab (ODYSSEY OUTCOMES)

Outcome Effect Evidence Strength
Major adverse cardiovascular events (MACE) 15 % relative risk reduction (HR 0.85; 95 % CI 0.78–0.93; p < 0.001) High‑quality randomized trial (ACC)
Absolute risk reduction 1.6 % over median 2.8 years ACC
Number needed to treat 63 patients for 2.8 years to prevent one MACE ACC
All‑cause mortality (ESC analysis) 22 % relative risk reduction (HR 0.78; 95 % CI 0.65–0.94; p = 0.01) Class IIa evidence (ESC)
Mortality trend with LDL‑C Linear decline in mortality down to LDL‑C ≈ 30 mg/dL (adjusted p = 0.017) ESC

LDL‑C Lowering Achieved with Alirocumab

  • The ACC reports a 48–59 % reduction in LDL‑C from baseline with alirocumab. [29][30]
  • Median LDL‑C at 12 months was 48 mg/dL with alirocumab versus 96 mg/dL with placebo. 29
  • 42 % of treated patients achieved LDL‑C < 25 mg/dL. 29

Safety Profile

  • No excess of muscle‑related events, liver enzyme elevations, neurocognitive disorders, or hemorrhagic stroke over 2.8 years (ACC). 29
  • Very low LDL‑C levels (<25 mg/dL) were not associated with safety concerns (ESC). [31][32]
  • Injection‑site reactions were slightly more common with alirocumab (3.8 % vs 2.1 % with placebo) and were generally mild. 29

Dose‑Titration Algorithm (Based on ODYSSEY OUTCOMES)

  • Up‑titration: If LDL‑C ≥ 70 mg/dL at week 8, increase alirocumab from 75 mg to 150 mg every 2 weeks at week 12; 27.7 % of participants required this adjustment. (ACC)
  • Down‑titration: Patients on 150 mg who achieve two consecutive LDL‑C < 25 mg/dL may be reduced back to 75 mg; 30.8 % of those up‑titrated were subsequently down‑titrated. (ACC)
  • Temporary discontinuation: If two consecutive LDL‑C < 15 mg/dL on 75 mg, consider stopping therapy; 7.7 % switched to placebo due to very low LDL‑C. (ACC)

Special Populations – Diabetes Mellitus

  • The American Diabetes Association (ADA) recommends prioritizing alirocumab in diabetic patients with ASCVD because they experience a 2.3 % absolute risk reduction versus 1.2 % in non‑diabetic patients. 30
  • No adverse impact on HbA1c or fasting glucose was observed with alirocumab (ADA).

Summary of Recommendations

  • Stepwise approach: high‑intensity statin → add ezetimibe if LDL‑C ≥ 70 mg/dL → add alirocumab for very high‑risk patients not reaching target. (ACC, ADA)
  • Target LDL‑C: <55 mg/dL and ≥50 % reduction from baseline; aim for 25–50 mg/dL when feasible. (ACC)
  • Monitoring: lipid panel at baseline, 4–12 weeks after each therapy change, and annually thereafter. (ACC)

All facts are derived from cited randomized trial data and guideline‑level recommendations (ACC, ADA, ESC). Each bullet includes the corresponding citation identifier.

Evolocumab as First‑Line PCSK9 Inhibitor for Patients with ASCVD or Heterozygous Familial Hypercholesterolemia

1. Guideline Recommendation (ACC)

  • The 2022 ACC Expert Consensus Decision Pathway recommends evolocumab (Repatha) as the first‑line PCSK9 inhibitor for patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia who have not achieved LDL‑C goals despite maximally tolerated statin therapy with or without ezetimibe. 33

2. Eligibility for PCSK9 Inhibition (ACC)

  • LDL‑C threshold: Patients with clinical ASCVD must have a current LDL‑C ≥ 70 mg/dL despite maximally tolerated statin + ezetimibe before a PCSK9 inhibitor is considered. 33
  • Very‑high‑risk target: For very‑high‑risk patients, aim for LDL‑C < 55 mg/dL and at least a 50 % reduction from baseline. 34

3. First‑Line Therapy: Evolocumab (ACC)

  • Cardiovascular outcomes: In the FOURIER trial (27,564 patients, median follow‑up 2.2 years), evolocumab produced a 15 % relative risk reduction in major adverse cardiovascular events (MACE) with proven mortality and morbidity benefits. 33
  • LDL‑C lowering: Evolocumab provides an additional 50‑60 % reduction in LDL‑C when added to statin ± ezetimibe (clinical trial data). (Evidence level not explicitly stated in source.)

4. Situations Favoring Inclisiran (ACC)

  • Adherence concerns: Patients who repeatedly miss bi‑weekly or monthly injections may benefit from inclisiran’s 6‑month dosing interval. 33
  • Intolerance to monoclonal antibodies: When a patient experiences adverse effects from both evolocumab and alirocumab, inclisiran is a reasonable alternative. 33
  • Inability to self‑inject: Patients unable to self‑administer injections but able to attend semi‑annual provider visits may prefer inclisiran. 33

5. Inclisiran Evidence (ACC)

  • Lack of outcome data: No completed cardiovascular outcomes trials for inclisiran; ongoing ORION‑4 and VICTORION studies are expected to report results in several years. 35
  • Mechanism of action: Inclisiran is a small‑interfering RNA (siRNA) that silences hepatic PCSK9 mRNA, reducing PCSK9 synthesis intracellularly. 35
  • Dosing schedule: Initial dose, repeat at 3 months, then every 6 months thereafter. 35
  • LDL‑C lowering efficacy: Pooled analyses show a 44‑54 % LDL‑C reduction (average ≈ 50.7 % at day 510). 35
  • Safety profile: Injection‑site reactions occur in ≈ 5 % of patients (vs 0.7 % with placebo); otherwise safety is comparable to placebo. 35

6. Monitoring & Follow‑Up (ACC)

  • LDL‑C assessment:
    • Evolocumab – measure LDL‑C 4 weeks after initiation.
    • Inclisiran – measure LDL‑C 90 days after the first dose, then every 6 months. 35
  • Target achievement:
    • Very‑high‑risk: LDL‑C < 55 mg/dL with ≥50 % reduction.
    • High‑risk: LDL‑C < 70 mg/dL.
    • Secondary: Non‑HDL‑C < 85 mg/dL for very‑high‑risk patients. All targets derived from ACC‑endorsed recommendations. 34
  • Safety monitoring: No routine laboratory tests required; focus on injection‑site reactions (≈ 5 % with inclisiran). 35

7. Cost, Access, and Reimbursement (ACC)

  • Prior authorization requirements: Most payers mandate documentation of maximally tolerated high‑intensity statin + ezetimibe before approving any PCSK9 inhibitor. 34
  • Specialist prescribing: In several countries, PCSK9 inhibitors are restricted to specialist (cardiology/endocrinology) prescription. 34
  • Inclisiran reimbursement: Varies by jurisdiction; some payers request cardiovascular outcomes data that are not yet available. 34

8. Pitfalls to Avoid (ACC)

  • Do not use inclisiran as first‑line PCSK9 therapy because there is currently no evidence of additional LDL‑C lowering or cardiovascular outcome benefit compared with monoclonal antibodies. 33
  • Do not skip ezetimibe before initiating a PCSK9 inhibitor; ezetimibe provides an additional 15‑20 % LDL‑C reduction at lower cost and is required by many guidelines and reimbursement policies. 34

All facts are extracted from ACC‑endorsed sources and are presented with the corresponding citation identifiers.

Indefinite Duration of PCSK9 Inhibitor Therapy in ASCVD and Heterozygous Familial Hypercholesterolemia

Evidence Supporting Continuous Therapy

Safety Profile of Long‑Term Use

Guideline Recommendations

Monitoring Schedule

LDL‑C Target Goals

Dose Adjustment and Rebound Considerations

Continuation of Background Lipid‑Lowering Therapy

Situations Warranting Discontinuation

REFERENCES